Clinical Trial

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study intends to explore the efficacy and safety of PD-L1 inhibitor Adebrelimab combined with the CDK4/6 inhibitor Dalpcicilib and standard endocrine therapy given as neoadjuvant treatment in stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-13; most recent amendment 2025-08-19.
Status change: Recruiting → Active, Not Recruiting 2025-08-19
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06599216
Lead Sponsor Harbin Medical University
Conditions Breast Cancer, HR+/HER2- Breast Cancer
Enrollment 30 participants
Start Date 2024-10-08
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-21